5 Literaturverzeichnis

Adward AG. Subjective response to Neuroleptics in Schizophrenia. Schizophrenia Bulletin (1993).19 (3):609 – 616.

Aitchison KJ, Munro J, Wright P, Smith S, Makoff AJ, Sachse C, Sham PC, Murray RM, Collier DA, Kerwin RW. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol (1999). 48:388-394.

Altamura AC, Tacchini GL, Maes M. Haloperidol plasma „threshold“ levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. Eur Neuropsychopharmacol (1955).5 (Suppl):55-58.

Altamura C, Mauri M, Cavallaio R, Colacuricio F, Gorni A, Bareggi S. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences. Prog Neuropsychopharmacol Biol Psychiatry (1988) .12 (5):689-694.

Armstrong M, Daly AK, Blennerhassett R, Rerrier N, Idle JR. Antipsychotic drug-induced disorders in schizophrenics in relation to CYP2D6 genotype. British Journal of Psychiatry (1997).170:23-26.

Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol (1995). 15 (3):211-216.

Balant-Gorgia AE, Balant LP, Garrone G. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther Drug Monit 1989. 11:415-420.

Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol (1998): 13 Suppl 3:49-57.

Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry (1989).154:672-676.

Bech P, Rafaelsen OJ, Kramp P, Bowlwig TG. The Mania Rating Scale: scale construction and inter-observer agreement. Neuropharmacology (1978).17:430-431.

Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Springer-Verlag Berlin, Heidelberg, New York (2000). p 132.

Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Liao X-M, Wang K-Y, Reviriego J, Isilius I, Sjöquist F. Pronounced differences between native Chinese and

Swedish population in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther (1992). 51:388-397.

Bertilsson L, Mellström B, Sjöqvist F, Martensson B, Asberg M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet (1981). I:560-561.

Bouman WP, Pinner G. Use of atypical antipsychotic drugs in old age psychiatry. Advances in Psychiatric Treatment (2002). 8:49-58.

Breyer U. Metabolism of the phenothiazine drug perazine by liver and lung microsomes from various species. Biochem. Pharmacol. (1971).20:3341-74.

Breyer-Pfaff U, Nill K, Schied HW, Gaertner H J. Single-dose kinetics of the neuroleptic drug perazine in psychotic patients. Psychopharmacology (1988).95: 374-377.

Chakraborty BS, Hubbard JW, Hawes EM et al. Interkonversions between haloperidol and reduced haloperidol in healthy volonteers. Eur J Clin Pharmacol (1989). 37:45-48.

Chang WH, Hwu HG, Lane HY, Lind SK, Chen TY, Chen H, Wie HL, Lin WL, Lin HN. Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients. Psychiatry Res (1991).38 (3):215-225.

Coryll W, Miller DD, Perry PJ. Haloperidol plasma levels and dose Optimization. Am J Psychiatry (1998). 155 (1) :48-53.

Dahl AA, Lowert A, Asserson S, Bjarking L, Berglund J, Kristensen F, et al. Hydroxylation polymorphisms of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark. Hum Psychopharmacology (1998).13:509-511.

Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics (1993). 3:61-70.

Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet (2002). 41(7):453-470.

Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelmann-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Stehen VM, Wolf CR, Zanger UM, . Nomenclature for human CYP2D6 Alleles. Pharmacogenetics (1996). 6:193-201.

Darby JK, Pasta DJ, Dabiri L, Clark L, Mosbacher D. Haloperidol Dose and Blood Level Variability: Toxicity and Interindividual and Intraindividual Variability in the Nonresponder Patient in the Clinical Practice Setting. J Clin

Psychopharmacol (1995). Vol 15/ 5:334-340.

Delay J, Deniker P. Die Behandlung der Psychosen mit einer von der Winterschlafmethode abgeleiteten neurolytischen Methode. In: Selbach H (Herausg.) Pharmako-Psychiatrie. Darmstadt: Wissenschaftliche Buchgemeinschaft (1952). S 85-91.

Dilling H, Mombour W, Schmidt MH (Hrsg). Verlag Hans Huber Bern Göttingen Toronto. WHO Internationale Klassifikation psychischer Störungen ICD-10(1991).Kapitel V (F).

Dixon L.B., Lehman A.F., Levine J: Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin (1995). 21 (4):607-619.

Doddi S, Rifkin A, Karajg B, Cooper T, Borenstein M. Blood levels of haloperidol and clinical outcome in schizophrenia. J Clin Psychopharmacol (1994). 14 (3):187-195.

Eichelbaum M, Spannbruckner N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) .17:153-155.

Froemming JS, Francis Lam YW, JannMW and Davis CM. Clinical pahrmacokinetics of haloperidol. Clin Pharmacokinet (1989). 17:396-423.

Gaebel W, Müller–Oerlinghausen B, Schley J. Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia. Progr Neuro-Psychopharmacol and Biol Psychiat (1992). 16:891-900.

Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry (2000). 61 Suppl (3):16-21.

Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (1988). 331:442-446.

Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al. Assessment of the predictive power of genotypes for the in–vivo catalytic function of CYP2D6 in a German population Pharmacogenetics (1997). 8:15-26.

Grohmann R, Rüther E, Schmidt L. Unerwünschte Wirkungen von Antipsychotika in der Routinebehandlung. Psychopharmakotherapie / 1.Jahrgang (1994). 2:40-49.

Grohmann R, Rüther E, Schmidt LG. Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMÜP-Studie. Springer-Verlag. Berlin Heidelberg New York Tokio (1994).

Guy W (ed) ECDEU. Abnormal involuntary movement scale. Assessment manual for Psychopharmacology. US Department of Health, Education and Welfare, Rockville, Md. (1976). Pp 534-537.

Hamilton M. Development of al rating scale for primary depressive illness. Brit. J. Soc. Clin. Psychol. (1967).6:278-296.

Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol (1987). 23:482-485.

Jaen JC, Caprathe BW, Pugsley TA, Wise LD, Akunne H. Evaluation of the effects of the enantionmers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J Med Chem (1993) 36: 3929-3936.

Jeste DV, Caligiuri MP, Paulsen JS. Risk of tardive Dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Archives of General Psychiatry (1995). 52:756-765.

Kalow W, Goedde HW and Agarwal DP. Ethic differences in reactions to drugs and xenobiotics. Progress in clinical and biological research. (1986). Vol 214, Liss AR, inc., New York.

Kaname K, Yoshiiake FK. P450 and Human Cancer. Jpn. J. Cancer Res. (1991). 82:1325-1335.

Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer HN, Kasper S. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 27 (1998) 32 (2):101-106.

Kay SR, Fisbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia bulletin (1987).Vol 13, No 2: 261-275.

Kirch DG, Bieglow LB, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ. Serum haloperidol concentration and clinical response in schizophrenia. Schizophr Bull (1988) 14 (2): 283-289.

Kresse M, Sxhley J, Müller-Oerlinghausen B. Reliable routine method for determination of perazine in serum by thin-layer Chromatography with an internal standard. J. Chromatogr. (1980). 183:475-4782.

Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet (1999) 37 (6): 435-456.

Lane HY, Chang WH, Chang YC, Hu OY, Lin HN, Jann MW, et al. Dose-dependent reduced haloperidol/haldoperidol ratios: influence of patient-

related variables. Psychiatry Res (1997a) 72: 127-132.

Lane HY, Hu OY-P, Jann MW et al. Dextromethorphan phenotypin and haloperidol disposition in schizophrenic patients. Psychiatry Res (1997b) 69:105-111.

Lane HY, Lin HN, HuOY, Chen CC, Jann MW, Chang WH. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Prog Neuropsychopharmacol Biol Psychiatry (1997c). 21 (2):299-311.

Lehman AF, Steinwachs DM. At issue: Translating Research into Practice: The schizophrenia Patient outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin (1998). 24 (1):1-10.

Leroux JM, Elia E, Jacquet M, Pommery J, Levron JC, Bouhours P, Sechter D. Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (1994). 18 (2):347-353.

Leucht S, Hartung B. Perazine for schizophrenia. Cochrane Database Syst Rev (2002). 1: CD002832.

Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, Stephnos MJ et al. Fluphenazin dose, clinical response and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry (1990). 47:761-768.

Lewis DFV, Watson E, Lake BG. Evolution of the Cytochrom P450 Superfamily: Sequence Alignments and Pharmacogenetics. Mutat Res (1998). 410:245-270.

Linde O. Pharmakopsychiatrie im Wandel der Zeit. Tilia-Verlag Klingenmünster (1988).

Llerena A, Alm C, Dahl ML, Ekquist B, Bertilsson I. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype. Ther Drug Monit (1992a) 14: 92-97.

Llerena A, Dahl ML, Ekquist B, Bertilsson I. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor meabolizers. Ther Drug Monit (1992b) 14: 261-264.

Lohse MJ, Müller-Oerlinghausen B. Psychopharmaka, in Arzneimittelreport 97, U. Schwabe Editor., Gustav Fischer Verlag, Stuttgart(1997). pp 453-74.

Lou YC, Liu Y, Bertilsson L, Sjöquist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) II: 852-853.

Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet (1977). II : 584-586.

McCreadie RG, Robertson LJ, Wiles DH. The Nithsdale schizoprenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiatry (1992).160:793-799.

Miller CH, Hummer M, Oberbauer H, Kurzthaler I, DeCol C, Fleischhacker WW. Risk factors fort he development of neuroleptic induced akathisia. Eur Neuropsychopharmacol (1997). 7 (1):51-55.

Möller HJ, Laux G, Deister A. Psychiatrie. Hippokrates-Verlag Stuttgart (1996). 127-129.

Nyberg S, Farade L, Halldin C, Dahl ML, Bertilsson I. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry (1995). 152:173-178.

Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit (2000). 22(1): 118-121.

Palao DJ, Arauxo A, Brunet M, Bernado M, Haro JM, Ferrer J, Gonzalez-Monclus E. Haloperidol: Therapeutic window in schizophrenia. Journal of Clin Psychopharmacol (1994). 14 (5):303-310.

Pan L, Belpaire FM. In vitro study on the involvement of CYP1A2, CPY2D6 und CYP3A4 in the metabolism of haloperidol und reduced haloperidol. Eur J Clin Pharmacol (1999). 55 (8): 599-604.

Pietzker A, Poppenberg A, Schley J, Müller-Oerlinghausen B. Outcome and Risks of Ultra-Long-Term Treatment with an Oral Neuroleptic Drug. Arch Psychiatr Nervenkr (1981). 229:315-329.

Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML, Bertilsson L. Plasma concentration of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol (2001). 52 (3): 265-271.

Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M. Debrisoquin hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klein Wochenschr (1988). 66 (Suppl Xl): 87-97.

Sachse C, Brockmöller J, Bauer S, Roots I: Cytochrom P450 2C6 Variants in a Caucasian Population: Allele Frequencies and Phenotypic Consequences. Am. J. Hum. Genet. (1997). 60: 284-295.

Sachse C, Brockmöller J, Hildebrand M, Müller K, Roots I. Correctness of Predictions of the CYP2D6 Phenotype confirmed by genotyping 47

intermediate and poor metabolizers of debrisoquine. Pharmacogenetics (1998).8:181-185.

Sachse C. Erbliche Polymorphismen von Cytochrom P450-2D6: Identifizierung, Populationshäufigkeit und Bedeutung für Arzneimittelwirkungen. Dissertation an der Mathematisch-Naturwissenschaftlichen Fakultät I der Humboldt-Universität zu Berlin. (1998). Seite 18.

Saß H, Wittchen UH, Zaudig M (Hrsg). Diagnostisches und Statistisches Manual Psychischer Störungen. DSM-IV. Hogrefe, Göttingen.(1996).

Schley J, Riedel E, Müller-Oerlinghausen B. Metabolism and execretion of the neuroleptic drug perazine in healthy volonteers. Int Pharmacopsychiatr (1981).16: 201-211.

Schwabe U, Paffrath D. Arzneiverordnungs-Report 2002.Springer-Verlag Berlin Heidelberg New York (2003):p661.

Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johannson I, Sjoqvist F. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol (2000). 56 (9-10): 679-683.

Scordo MG, Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics (2002). 3 (2): 201-218.

Shibata N, Ohnuma T, Baba H, Shimada H, Takahashi T, Arai H. Genetic association between cytochrome P450-2D6 gene polymorphism and plasma concentration of haloperidol in Japanese schizophrenics. Psychiatr. Genet (1999). 9 (3):145-148.

Simpson GM, Agnus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl (1970). 212:11-19.

Someya T, Shibasaki M, Noguchi T, Takahashi S, Inaba T. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. J Clin Psychopharmacol (1992) 12: 169-174.

Someya T, Suzuki Y, Shimoda K, Hirokane G, Morita S, Yokono A, Inoue Y, Takahashi S. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psychiatry Clin Neurosci (1999) 53:593-597.

Störmer E, Brockmöller J, Roots I, Schmider J. Cytochrome P–450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (2000). 151:312-320.

Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, Hayashi K. Effects of the CYP2D6 genotype on the steady-state plasma concentration

of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics (1997). 7:415-418.

Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AJ. Polymorphic hydroxylation of debrisoquine. Lancet (1977). 2:718.

Tyndale RF, Kalow W und Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450 2D6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol (1991). 31:655-660.

Ulrich S, Neuhof S, Braun V, Meyer FP. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry (1998). 31 (5):163-169.

Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry (1990). 47:754 – 758.

Van Putten T: Why do schizophrenic Patients refuse to take their Drugs? Arch Gen Psychiatry (1974). 31:67 – 72.

Volavka J, Cooper TB, Meisner M, Bitter I, Czobor P, Jaeger J. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report. Psychopharmacol Bull (1990).26 (1):13-17.

Walter S, Bauer S, Roots I, Brockmöller J. Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr Biomed Sci Appl 11 (1998) 720:231-237.

Walter S. Bedeutung der erblichen Polymorphismen von Cytochrom P 450 2D6 für den Metabolismus und die Pharmakokinetik von Antipsychotika. Dissertation HU Berlin 2000.